AI–scientist collaboration ↗
An editorial split of a real collaboration into a method question and an ILC disease hypothesis.
Frozen card revision. This is the recorded reading, not an automatically refreshed view. Current card ↗
Frontier Science · TOPIC v1
Immune signals in lobular cancer
Can an AI-surfaced immune signal inform treatment research?
2026-09-07 11:00:45.083 UTC · Last recorded update
CURRENT READING
Validation in additional data and tissue reported. Treatment benefit is unproven.
Recorded editorial state, not a maturity score
- AI hypothesisRecorded
- Additional datasetRecorded
- Tumor tissueRecorded
- Treatment effectUnverified
New question opened · v1
Opened a separate card: a method claim and a disease finding need different tests.
Permanent link to this revision ↗01 / WHAT WE TRACK
Can an AI-surfaced immune signal inform treatment research?
02 / EVIDENCE & TECHNOLOGY
Invasive lobular carcinoma (ILC) / immune signatures / T cells
03 / EDITORIAL READING
Track the gap between discovery and treatment. Separate method evaluation from the disease claim so each can develop independently.
04 / WHAT REMAINS UNKNOWN
Validation within the collaboration is not replication by an independent team. It does not establish immunotherapy efficacy.
05 / NEXT CHECK
Peer review, replication by another team and prospective tests of the treatment hypothesis.
A hypothesis to keep honest
HYPOTHESIS · NOT YET TESTEDImmune signals may identify new research questions within ILC.
What would change our view: Reconsider if the signal fails independent replication or does not relate to treatment response.
A prospective test proposal, not a prediction score. A graph connection does not validate this hypothesis.
Linked people & organizations
Open an entity to find its cardsINSTITUTION / INFRASTRUCTUREProvidence Swedish / PARC ↗
AutoDiscovery research collaboration and planned deployment expansion.
Evidence: Ai2 ↗
Related questions, optional follows
Map ↗Latest card updates
Latest 5 · editorial record dates- v1 · 2026-09-07 11:00:45.083 UTCNew question opened
Opened a separate card: a method claim and a disease finding need different tests.
Reading at the time: Validation in additional data and tissue reported. Treatment benefit is unproven.
Earlier updates (0)
Earlier entries will appear here once more than five reader-facing revisions have accumulated.
Source-event timeline (different from editorial revisions)
Collaboration expansion announced; deployment being established.
Evidence: Ai2 ↗
Preprint v1 posted. Abstract checked; not peer-reviewed.
Historical events were assembled through source research. They do not imply the magazine tracked them at the time.
Source dates and verification scope
Ai2 and Providence Swedish partner to advance AI-assisted discovery ↗
Ai2 · 2026-08-27 · institution
Surprisal-based large language models reveal immunologic insights in lobular breast cancer ↗
Majumder et al. / medRxiv · 2026-08-31 · preprint-abstract